 Your new post is loading...
|
Scooped by
HAS-veille
August 21, 2023 4:35 AM
|
This case series investigates whether analysis of clinical history via a language model system improves diagnostic accuracy in patients with complex and delayed diagnoses.
|
|
Scooped by
HAS-veille
August 21, 2023 4:05 AM
|
|
|
Scooped by
HAS-veille
August 9, 2023 4:51 AM
|
Artificial intelligence, as a nonhuman entity, is increasingly used to inform, direct, or supplant nursing care and clinical decision-making. The boundaries between human- and nonhuman-drive
|
|
Scooped by
HAS-veille
August 7, 2023 9:03 AM
|
Artificial Intelligence in U.S. Health Care The authors, both employed by a company providing consulting services for public and private health care organizations, examine the use of AI i
|
|
Scooped by
HAS-veille
August 7, 2023 8:34 AM
|
|
|
Scooped by
HAS-veille
August 7, 2023 8:19 AM
|
Some countries are advanced than others in offering reimbursement opportunity. Among the standardized uropean reimbursement pathways
|
|
Scooped by
HAS-veille
August 7, 2023 8:13 AM
|
Background: Telehealth interventions have become increasingly important in health care provision, particularly during the COVID-19 pandemic. Video calls have emerged as a popular and effective method for delivering telehealth services; however, barriers limit the adoption among allied health professionals and nurses.
Objective: This review aimed to identify and map the perceived barriers to the use of video call–based telehealth interventions among allied health professionals and nurses.
Conclusions: This review identified key barriers to video call–based telehealth use by allied health professionals and nurses, which can foster the development of stable infrastructure, education, training, guidelines, policies, and support systems to improve telehealth services. Further research is necessary to identify potential solutions to the identified barriers.
|
|
Scooped by
HAS-veille
August 7, 2023 8:02 AM
|
Background: Digital therapeutics are patient-facing digital health interventions that can significantly alter the health care landscape. Despite digital therapeutics being used to successfully treat a range of conditions, their uptake in health systems remains limited. Understanding the full spectrum of uptake factors is essential to identify ways in which policy makers and providers can facilitate the adoption of effective digital therapeutics within a health system, as well as the steps developers can take to assist in the deployment of products.
Objective: In this review, we aimed to map the most frequently discussed factors that determine the integration of digital therapeutics into health systems and practical use of digital therapeutics by patients and professionals.
Conclusions: The map of factors developed in this review offers a multistakeholder approach to recognizing the uptake factors of digital therapeutics in the health care pathway and provides an analytical tool for policy makers to assess their health system’s readiness for digital therapeutics.
|
|
Scooped by
HAS-veille
July 13, 2023 4:03 AM
|
Dozens of frameworks have been proposed to assess evidence for digital health interventions (DHIs), but existing frameworks may not facilitate DHI evidence reviews that meet the needs of stakeholder organizations including payers, health systems, trade organizations, and others. These organizations may benefit from a DHI assessment framework that is both rigorous and rapid. Here we propose a framework to assess Evidence in Digital health for EFfectiveness of INterventions with Evaluative Depth (Evidence DEFINED). Designed for real-world use, the Evidence DEFINED Quick Start Guide may help streamline DHI assessment. A checklist is provided summarizing high-priority evidence considerations in digital health. Evidence-to-recommendation guidelines are proposed, specifying degrees of adoption that may be appropriate for a range of evidence quality levels. Evidence DEFINED differs from prior frameworks in its inclusion of unique elements designed for rigor and speed. Rigor is increased by addressing three gaps in prior frameworks. First, prior frameworks are not adapted adequately to address evidence considerations that are unique to digital health. Second, prior frameworks do not specify evidence quality criteria requiring increased vigilance for DHIs in the current regulatory context. Third, extant frameworks rarely leverage established, robust methodologies that were developed for non-digital interventions. Speed is achieved in the Evidence DEFINED Framework through screening optimization and deprioritization of steps that may have limited value. The primary goals of Evidence DEFINED are to a) facilitate standardized, rapid, rigorous DHI evidence assessment in organizations and b) guide digital health solutions providers who wish to generate evidence that drives DHI adoption.
|
|
Scooped by
HAS-veille
July 7, 2023 1:06 AM
|
This Viewpoint discusses how regulators across the world should approach the legal and ethical challenges, including privacy, device regulation, competition, intellectual property rights, cybersecurity, and liability, raised by the medical use of large language models.
|
|
Scooped by
HAS-veille
July 6, 2023 3:30 AM
|
This systematic review assesses US Food and Drug Administration (FDA) 501(k) clearance documents and marketing materials for adherence to guidelines for artificial intelligence– and machine learning–enabled medical devices.
|
|
Scooped by
HAS-veille
July 3, 2023 7:36 AM
|
Cardiovascular disease is one of the leading causes of death worldwide. Scarce resources and rising costs are pushing healthcare systems to their limits. There is an urgency to develop, optimize and evaluate technologies that provide more effective care for patients. Modern technologies, such as mobile health (mHealth) applications, can provide relief as a key strategy. To integrate digital interventions into care structures, a detailed impact assessment of all professional mHealth applications is needed. The aim of this study is to analyze the standardized tools used in the field of cardiovascular disease. The results show that questionnaires, usage logs, and key indicators are predominantly used. Although the identified mHealth interventions are specific to cardiovascular disease and thus require particular questions to evaluate apps, the user readiness, usability, or quality of life criteria are non-specific. Therefore, the results contribute to understanding how different mHealth interventions can be assessed, categorized, evaluated, and accepted.
|
|
Scooped by
HAS-veille
July 3, 2023 2:29 AM
|
Background: ChatGPT-4 is the latest release of a novel artificial intelligence (AI) chatbot able to answer freely formulated and complex questions. In the near future, ChatGPT could become the new standard for health care professionals and patients to access medical information. However, little is known about the quality of medical information provided by the AI.
Objective: We aimed to assess the reliability of medical information provided by ChatGPT.
Conclusions: ChatGPT provides medical information of comparable quality to available static internet information. Although currently of limited quality, large language models could become the future standard for patients and health care professionals to gather medical information.
|
|
|
Scooped by
HAS-veille
August 21, 2023 4:20 AM
|
Despite the renewed interest in Artificial Intelligence-based clinical decision support systems (AI-CDS), there is still a lack of empirical evidence …
|
|
Scooped by
HAS-veille
August 10, 2023 4:07 AM
|
|
|
Scooped by
HAS-veille
August 7, 2023 9:10 AM
|
To elaborate a concept for implementing digital health applications (DiHA), including prioritisation criteria (PC) for the Austrian context and an ove…
|
|
Scooped by
HAS-veille
August 7, 2023 8:49 AM
|
This systematic review examines information from the US Food and Drug Administration on all recently approved medical devices used in just-in-time interventions to assess how they operate and appraise the evidence supporting their performance and clinical effectiveness.
|
|
Scooped by
HAS-veille
August 7, 2023 8:20 AM
|
Monetization through reimbursement is complicated and a long journey with multiple steps. There are two most challenging milestones on the way
|
|
Scooped by
HAS-veille
August 7, 2023 8:14 AM
|
Background: Digital therapeutics (DTx), a class of software-based clinical interventions, are promising new technologies that can potentially prevent, manage, or treat a spectrum of medical disorders and diseases as well as deliver unprecedented portability for patients and scalability for health care providers. Their adoption and implementation were accelerated by the need for remote care during the COVID-19 pandemic, and awareness about their utility has rapidly grown among providers, payers, and regulators. Despite this, relatively little is known about the capacity of DTx to provide economic value in care.
Objective: This study aimed to systematically review and summarize the published evidence regarding the cost-effectiveness of clinical-grade mobile app–based DTx and explore the factors affecting such evaluations.
Conclusions: This systematic review supports the thesis that DTx interventions offer potential economic benefits. However, DTx economic analyses conducted to date exhibit important methodological shortcomings that must be addressed in future evaluations to reduce the uncertainty surrounding the widespread adoption of DTx interventions.
|
|
Scooped by
HAS-veille
August 7, 2023 8:05 AM
|
The launch of OpenAI’s GPT-3 model in June 2020 began a new era for conversational chatbots. While there are chatbots that do not use artificial intelligence (AI), conversational chatbots integrate AI language models that allow for back-and-forth conversation between an AI system and a human user. GPT-3, since upgraded to GPT-4, harnesses a natural language processing technique called sentence embedding and allows for conversations with users that are more nuanced and realistic than before. The launch of this model came in the first few months of the COVID-19 pandemic, where increases in health care needs globally combined with social distancing measures made virtual medicine more relevant than ever. GPT-3 and other conversational models have been used for a wide variety of medical purposes, from providing basic COVID-19–related guidelines to personalized medical advice and even prescriptions. The line between medical professionals and conversational chatbots is somewhat blurred, notably in hard-to-reach communities where the chatbot replaced face-to-face health care. Considering these blurred lines and the circumstances accelerating the adoption of conversational chatbots globally, we analyze the use of these tools from an ethical perspective. Notably, we map out the many types of risks in the use of conversational chatbots in medicine to the principles of medical ethics. In doing so, we propose a framework for better understanding the effects of these chatbots on both patients and the medical field more broadly, with the hope of informing safe and appropriate future developments.
|
|
Scooped by
HAS-veille
August 7, 2023 6:54 AM
|
Background: Mental disorders cause substantial health-related burden worldwide. Mobile health interventions are increasingly being used to promote mental health and well-being, as they could improve access to treatment and reduce associated costs. Behavior change is an important feature of interventions aimed at improving mental health and well-being. There is a need to discern the active components that can promote behavior change in such interventions and ultimately improve users’ mental health.
Conclusions: Mental health CAs mostly targeted various mental health issues such as stress, anxiety, and depression, reflecting a broad intervention focus. The most common BCTs identified serve to promote the self-management of mental disorders with few therapeutic elements. CA developers should consider the quality of information, user confidentiality, access, and emergency management when designing mental health CAs. Future research should assess the role of artificial intelligence in promoting behavior change within CAs and determine the choice of BCTs in evidence-based psychotherapies to enable systematic, consistent, and transparent development and evaluation of effective digital mental health interventions.
|
|
Scooped by
HAS-veille
July 7, 2023 2:59 AM
|
The rapid advancements in artificial intelligence (AI) have led to the development of sophisticated large language models (LLMs) such as GPT-4 and Bard. The potential implementation of LLMs in healthcare settings has already garnered considerable attention because of their diverse applications that include facilitating clinical documentation, obtaining insurance pre-authorization, summarizing research papers, or working as a chatbot to answer questions for patients about their specific data and concerns. While offering transformative potential, LLMs warrant a very cautious approach since these models are trained differently from AI-based medical technologies that are regulated already, especially within the critical context of caring for patients. The newest version, GPT-4, that was released in March, 2023, brings the potentials of this technology to support multiple medical tasks; and risks from mishandling results it provides to varying reliability to a new level. Besides being an advanced LLM, it will be able to read texts on images and analyze the context of those images. The regulation of GPT-4 and generative AI in medicine and healthcare without damaging their exciting and transformative potential is a timely and critical challenge to ensure safety, maintain ethical standards, and protect patient privacy. We argue that regulatory oversight should assure medical professionals and patients can use LLMs without causing harm or compromising their data or privacy. This paper summarizes our practical recommendations for what we can expect from regulators to bring this vision to reality.
|
|
Scooped by
HAS-veille
July 6, 2023 8:09 AM
|
Given the impact artificial intelligence (AI)–based medical technologies (hardware devices, software programs, and mobile apps) can have on society, debates regarding the principles behind their development and deployment are emerging. Using the biopsychosocial model applied in psychiatry and other fields of medicine as our foundation, we propose a novel 3-step framework to guide industry developers of AI-based medical tools as well as health care regulatory agencies on how to decide if a product should be launched—a “Go or No-Go” approach. More specifically, our novel framework places stakeholders’ (patients, health care professionals, industry, and government institutions) safety at its core by asking developers to demonstrate the biological-psychological (impact on physical and mental health), economic, and social value of their AI tool before it is launched. We also introduce a novel cost-effective, time-sensitive, and safety-oriented mixed quantitative and qualitative clinical phased trial approach to help industry and government health care regulatory agencies test and deliberate on whether to launch these AI-based medical technologies. To our knowledge, our biological-psychological, economic, and social (BPES) framework and mixed method phased trial approach are the first to place the Hippocratic Oath of “Do No Harm” at the center of developers’, implementers’, regulators’, and users’ mindsets when determining whether an AI-based medical technology is safe to launch. Moreover, as the welfare of AI users and developers becomes a greater concern, our framework’s novel safety feature will allow it to complement existing and future AI reporting guidelines.
|
|
Scooped by
HAS-veille
July 5, 2023 7:21 AM
|
|
|
Scooped by
HAS-veille
July 3, 2023 2:32 AM
|
Background: Multimorbidity, the presence of more than one condition in a single individual, is a global health issue in primary care. Multimorbid patients tend to have a poor quality of life and suffer from a complicated care process. Clinical decision support systems (CDSSs) and telemedicine are the common information and communication technologies that have been used to reduce the complexity of patient management. However, each element of telemedicine and CDSSs is often examined separately and with great variability. Telemedicine has been used for simple patient education as well as more complex consultations and case management. For CDSSs, there is variability in data inputs, intended users, and outputs. Thus, there are several gaps in knowledge about how to integrate CDSSs into telemedicine and to what extent these integrated technological interventions can help improve patient outcomes for those with multimorbidity.
Objective: Our aims were to (1) broadly review system designs for CDSSs that have been integrated into each function of telemedicine for multimorbid patients in primary care, (2) summarize the effectiveness of the interventions, and (3) identify gaps in the literature.
Conclusions: Telemedicine and CDSSs have a role in supporting patients with multimorbidity. CDSSs can likely be integrated into telehealth services to improve the quality and accessibility of care. However, issues surrounding such interventions need to be further explored. These issues include expanding the spectrum of medical conditions examined; examining tasks of CDSSs, particularly for screening and diagnosis of multiple conditions; and exploring the role of the patient as the direct user of the CDSS.
|
Scoop.it!
